China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III clinical study for its 23-valent pneumococcal polysaccharide vaccine. The study is designed as a randomized, blind, similar vaccine-controlled trial, expected to enroll 1920 healthy subjects aged two years and older.
Targeting Invasive Pneumococcal Diseases
The 23-valent pneumococcal polysaccharide vaccine is indicated for the prevention of invasive pneumococcal diseases in individuals over two years of age, with particular relevance for those over 60 years old. The vaccine comprises 23 pneumococcal serotype polysaccharide antigens, which can protect against pneumonia, meningitis, otitis media, and bacteremia caused by pneumococcal infection. It covers nearly 90% of the most commonly reported serotypes responsible for pneumococcal diseases.
Clinical Progress and Safety Profile
The product initiated its Phase I clinical study in December 2021 and has since demonstrated a favorable safety and immunogenicity profile. The progression to Phase III signifies a significant step forward in the development of this vaccine, which aims to provide broad protection against pneumococcal infections.-Fineline Info & Tech
